Articles of Interest

In January 2025, the Drug Enforcement Administration (DEA) introduced a proposed rule that could significantly reshape how addiction medicine is delivered across the country. Designed under the authority of the Ryan Haight Online Pharmacy Consumer Protection Act, the rule lays the groundwork for allowing certain controlled substances to be prescribed via telemedicine—without requiring...

Overview of the Final Rule The DEA and the Department of Health and Human Services (HHS) published a final rule titled “Expansion of Buprenorphine Treatment via Telemedicine Encounter” on January 17, 2025. This rule permits DEA-registered practitioners to prescribe buprenorphine, a Schedule III controlled substance approved by the FDA for treating opioid use disorder (OUD), through...

The Drug Enforcement Administration (DEA) just released a new regulation temporarily extending the COVID-era flexibilities for prescribing controlled substances via telemedicine. This third extension continues the “full set” of telemedicine prescribing flexibilities, referencing the two DEA letters that authorized telemedicine waivers, with a new expiration date of December 31, 2025....

A new rule posted on the Office of Management and Budget (OMB) registry suggests that the Drug Enforcement Administration (DEA) is planning an additional extension of COVID-19 flexibilities for telemedicine prescribing of controlled substances, beyond the current expiration date of December 31, 2024. A new rule posted on the Office of Management and Budget (OMB) registry suggests that...